Cardio Diagnostics Partners with AHP for Cardiovascular Testing Coverage
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 24 2026
0mins
Source: Newsfilter
- Partnership Coverage: Cardio Diagnostics has partnered with Atlas Healthcare Physicians in Southern California to provide coverage for Epi+Gen CHD™ and PrecisionCHD™ tests starting May 2026, marking a significant expansion in the field of precision cardiovascular medicine.
- Testing Advantages: Epi+Gen CHD™ assesses the three-year risk of coronary heart disease events through simple blood tests, while PrecisionCHD™ aids in personalized diagnosis based on unique molecular characteristics, significantly enhancing patient treatment outcomes and health management.
- Clinical Integration: These tests require no radiation or fasting, seamlessly integrating into clinical workflows and lowering implementation barriers for healthcare providers, thereby increasing early detection rates of cardiovascular diseases and reducing the high costs associated with delayed diagnoses.
- Strategic Implications: With cardiovascular disease being a leading cause of death in California according to the California Department of Public Health, this partnership not only enhances Cardio Diagnostics' market competitiveness but also provides crucial support for community health, aligning with the company's long-term strategy to expand access to precision medicine.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CDIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CDIO
About CDIO
Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cardio Diagnostics Partners with AHP for Cardiovascular Testing Coverage
- Partnership Coverage: Cardio Diagnostics has partnered with Atlas Healthcare Physicians in Southern California to provide coverage for Epi+Gen CHD™ and PrecisionCHD™ tests starting May 2026, marking a significant expansion in the field of precision cardiovascular medicine.
- Testing Advantages: Epi+Gen CHD™ assesses the three-year risk of coronary heart disease events through simple blood tests, while PrecisionCHD™ aids in personalized diagnosis based on unique molecular characteristics, significantly enhancing patient treatment outcomes and health management.
- Clinical Integration: These tests require no radiation or fasting, seamlessly integrating into clinical workflows and lowering implementation barriers for healthcare providers, thereby increasing early detection rates of cardiovascular diseases and reducing the high costs associated with delayed diagnoses.
- Strategic Implications: With cardiovascular disease being a leading cause of death in California according to the California Department of Public Health, this partnership not only enhances Cardio Diagnostics' market competitiveness but also provides crucial support for community health, aligning with the company's long-term strategy to expand access to precision medicine.
See More
Cardio Diagnostics Targets Cardiovascular Disease at National Conferences
- Cardiovascular Disease Challenge: Cardio Diagnostics will showcase its solutions at four national benefits conferences aimed at helping employers, brokers, and unions tackle cardiovascular disease (CVD), a leading driver of medical claims and productivity loss.
- Innovative Testing Technology: The company's Epi+Gen CHD™ and PrecisionCHD™ blood tests combine epigenetics, genetics, and AI to identify individuals at higher risk of heart attacks within the next three years, even when traditional risk factors appear normal, thereby assisting employers in reducing healthcare costs.
- Significant Cost Efficiency: With the HeartRisk™ platform, plan sponsors can benchmark cardiovascular risk across their workforce, project both direct and indirect costs, and target benefits where they can have the greatest impact, ultimately enhancing employee health and productivity.
- Industry Leadership Position: CEO Meesha Dogan emphasized the company's unique advantage in partnering with employers, brokers, and unions to reduce healthcare costs while improving employee health through early risk identification, showcasing the potential for dual benefits.
See More
Cardio Diagnostics Partners with IBN to Enhance Communication Strategy
- Strategic Partnership: Cardio Diagnostics Holdings Inc. has engaged IBN to enhance its corporate communications strategy, leveraging IBN's investor-focused distribution network to increase awareness in the cardiovascular disease prevention and detection sector, which is expected to attract more investor interest.
- Technological Innovation: The company’s Epi+Gen CHD™ test, developed using artificial intelligence and genomics, assesses a patient's three-year risk of coronary heart disease events, representing a significant breakthrough in precision medicine that could transform traditional cardiovascular disease management.
- Product Portfolio Expansion: With the introduction of PrecisionCHD™ and HeartRisk™, which aid in coronary heart disease detection and population-level cardiovascular risk assessment respectively, Cardio Diagnostics is enhancing its product line, increasing market competitiveness, and potentially driving sales growth.
- Market Influence: IBN's extensive experience of over 20 years and partnerships with more than 500 clients will enable Cardio Diagnostics to leverage over 5,000 news outlets and social media platforms to expand its market influence and enhance brand recognition.
See More
Cardio Diagnostics Partners with IBN to Enhance Communication Strategy
- Strategic Partnership: Cardio Diagnostics Holdings Inc. has engaged IBN to enhance its corporate communications strategy by leveraging IBN's investor-focused distribution network, which includes over 5,000 key syndication outlets, thereby increasing awareness in the cardiovascular disease prevention and detection sector.
- Technological Innovation: The company utilizes artificial intelligence and genomics to develop blood tests, launching products like Epi+Gen CHD™ and PrecisionCHD™, which aid in assessing and managing coronary heart disease risk, thus advancing precision medicine.
- Market Impact: By partnering with IBN, Cardio Diagnostics aims to expand its influence among investors and the public, capitalizing on IBN's 20 years of industry experience and millions of social media followers to drive future growth.
- Product Portfolio: Cardio Diagnostics offers products such as HeartRisk™ and CardioInnovate360™, which not only provide individual and population-level cardiovascular risk assessments but also support the discovery and development of cardiovascular therapies, further solidifying its market position.
See More
Applied Optoelectronics Reports Strong Q4, Shares Surge
- Earnings Beat: Applied Optoelectronics reported a fourth-quarter loss of only $0.01 per share, significantly better than the analyst consensus estimate of a $0.11 loss, indicating improvements in cost management and market demand, which boosts investor confidence.
- Strong Sales Performance: The company achieved quarterly sales of $134.274 million, surpassing the analyst consensus estimate of $134.120 million, suggesting that its products continue to gain competitive traction in the market, potentially driving future revenue growth.
- Stock Surge: Following the earnings report, Applied Optoelectronics shares jumped 20.4% to $64.69 in pre-market trading, reflecting market optimism about the company's future performance and likely attracting more investor interest.
- Positive Guidance: The company issued first-quarter sales guidance above market expectations, further solidifying its market position in the optoelectronics sector and indicating stable growth potential for the upcoming quarters.
See More
Etsy Sells Depop to eBay for $1.2 Billion
- Significant Transaction Value: Etsy has entered into a definitive agreement with eBay to sell its fashion marketplace Depop for approximately $1.2 billion in cash, which not only provides Etsy with substantial cash flow but also enhances its financial flexibility to support future strategic investments.
- Stock Price Surge: Etsy's shares jumped 15.5% to $50.86 in pre-market trading, reflecting a positive market reaction to the deal and increasing investor confidence in the company's future growth potential.
- Market Consolidation Trend: This transaction signifies further consolidation in the e-commerce sector, as eBay's acquisition of Depop will expand its influence in the fashion market, while Etsy can focus on its core business to improve operational efficiency.
- Strategic Focus Shift: By selling Depop, Etsy can reallocate resources to concentrate on growth within its primary platform, with expectations to drive long-term profitability through optimizing product lines and enhancing user experience.
See More
Cardio Diagnostics Partners with AHP for Cardiovascular Testing Coverage
- Partnership Coverage: Cardio Diagnostics has partnered with Atlas Healthcare Physicians in Southern California to provide coverage for Epi+Gen CHD™ and PrecisionCHD™ tests starting May 2026, marking a significant expansion in the field of precision cardiovascular medicine.
- Testing Advantages: Epi+Gen CHD™ assesses the three-year risk of coronary heart disease events through simple blood tests, while PrecisionCHD™ aids in personalized diagnosis based on unique molecular characteristics, significantly enhancing patient treatment outcomes and health management.
- Clinical Integration: These tests require no radiation or fasting, seamlessly integrating into clinical workflows and lowering implementation barriers for healthcare providers, thereby increasing early detection rates of cardiovascular diseases and reducing the high costs associated with delayed diagnoses.
- Strategic Implications: With cardiovascular disease being a leading cause of death in California according to the California Department of Public Health, this partnership not only enhances Cardio Diagnostics' market competitiveness but also provides crucial support for community health, aligning with the company's long-term strategy to expand access to precision medicine.
See More
Cardio Diagnostics Targets Cardiovascular Disease at National Conferences
- Cardiovascular Disease Challenge: Cardio Diagnostics will showcase its solutions at four national benefits conferences aimed at helping employers, brokers, and unions tackle cardiovascular disease (CVD), a leading driver of medical claims and productivity loss.
- Innovative Testing Technology: The company's Epi+Gen CHD™ and PrecisionCHD™ blood tests combine epigenetics, genetics, and AI to identify individuals at higher risk of heart attacks within the next three years, even when traditional risk factors appear normal, thereby assisting employers in reducing healthcare costs.
- Significant Cost Efficiency: With the HeartRisk™ platform, plan sponsors can benchmark cardiovascular risk across their workforce, project both direct and indirect costs, and target benefits where they can have the greatest impact, ultimately enhancing employee health and productivity.
- Industry Leadership Position: CEO Meesha Dogan emphasized the company's unique advantage in partnering with employers, brokers, and unions to reduce healthcare costs while improving employee health through early risk identification, showcasing the potential for dual benefits.
See More
Cardio Diagnostics Partners with IBN to Enhance Communication Strategy
- Strategic Partnership: Cardio Diagnostics Holdings Inc. has engaged IBN to enhance its corporate communications strategy, leveraging IBN's investor-focused distribution network to increase awareness in the cardiovascular disease prevention and detection sector, which is expected to attract more investor interest.
- Technological Innovation: The company’s Epi+Gen CHD™ test, developed using artificial intelligence and genomics, assesses a patient's three-year risk of coronary heart disease events, representing a significant breakthrough in precision medicine that could transform traditional cardiovascular disease management.
- Product Portfolio Expansion: With the introduction of PrecisionCHD™ and HeartRisk™, which aid in coronary heart disease detection and population-level cardiovascular risk assessment respectively, Cardio Diagnostics is enhancing its product line, increasing market competitiveness, and potentially driving sales growth.
- Market Influence: IBN's extensive experience of over 20 years and partnerships with more than 500 clients will enable Cardio Diagnostics to leverage over 5,000 news outlets and social media platforms to expand its market influence and enhance brand recognition.
See More
Cardio Diagnostics Partners with IBN to Enhance Communication Strategy
- Strategic Partnership: Cardio Diagnostics Holdings Inc. has engaged IBN to enhance its corporate communications strategy by leveraging IBN's investor-focused distribution network, which includes over 5,000 key syndication outlets, thereby increasing awareness in the cardiovascular disease prevention and detection sector.
- Technological Innovation: The company utilizes artificial intelligence and genomics to develop blood tests, launching products like Epi+Gen CHD™ and PrecisionCHD™, which aid in assessing and managing coronary heart disease risk, thus advancing precision medicine.
- Market Impact: By partnering with IBN, Cardio Diagnostics aims to expand its influence among investors and the public, capitalizing on IBN's 20 years of industry experience and millions of social media followers to drive future growth.
- Product Portfolio: Cardio Diagnostics offers products such as HeartRisk™ and CardioInnovate360™, which not only provide individual and population-level cardiovascular risk assessments but also support the discovery and development of cardiovascular therapies, further solidifying its market position.
See More
Applied Optoelectronics Reports Strong Q4, Shares Surge
- Earnings Beat: Applied Optoelectronics reported a fourth-quarter loss of only $0.01 per share, significantly better than the analyst consensus estimate of a $0.11 loss, indicating improvements in cost management and market demand, which boosts investor confidence.
- Strong Sales Performance: The company achieved quarterly sales of $134.274 million, surpassing the analyst consensus estimate of $134.120 million, suggesting that its products continue to gain competitive traction in the market, potentially driving future revenue growth.
- Stock Surge: Following the earnings report, Applied Optoelectronics shares jumped 20.4% to $64.69 in pre-market trading, reflecting market optimism about the company's future performance and likely attracting more investor interest.
- Positive Guidance: The company issued first-quarter sales guidance above market expectations, further solidifying its market position in the optoelectronics sector and indicating stable growth potential for the upcoming quarters.
See More
Etsy Sells Depop to eBay for $1.2 Billion
- Significant Transaction Value: Etsy has entered into a definitive agreement with eBay to sell its fashion marketplace Depop for approximately $1.2 billion in cash, which not only provides Etsy with substantial cash flow but also enhances its financial flexibility to support future strategic investments.
- Stock Price Surge: Etsy's shares jumped 15.5% to $50.86 in pre-market trading, reflecting a positive market reaction to the deal and increasing investor confidence in the company's future growth potential.
- Market Consolidation Trend: This transaction signifies further consolidation in the e-commerce sector, as eBay's acquisition of Depop will expand its influence in the fashion market, while Etsy can focus on its core business to improve operational efficiency.
- Strategic Focus Shift: By selling Depop, Etsy can reallocate resources to concentrate on growth within its primary platform, with expectations to drive long-term profitability through optimizing product lines and enhancing user experience.
See More
